Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.

@article{Honkoop1997MultipleCO,
  title={Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.},
  author={Aafke H. Honkoop and Elsken van der Wall and N Feller and Gerrit J Schuurhuis and Wjf J F Van der Vijgh and Epie Boven and Cees J. van Groeningen and Guiseppe Giaccone and Klaas Hoekman and Jan B Vermorken and John Wagstaff and Herbert M. Pinedo},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1997},
  volume={8 10},
  pages={
          957-62
        }
}
BACKGROUND In a previous study we applied doxorubicin and cyclophosphamide in a dose-intensive regimen with GM-CSF to patients with metastatic breast cancer (MBC). That treatment failed to prolong the remission duration compared to conventional-dose chemotherapy. In the present study we escalated the dosages of the same agents to: 1) determine the maximum tolerated dosages (MTD) when given for three cycles with G-CSF mobilised peripheral blood progenitor cell (PBPC) reinfusion and 2) evaluate… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 21 REFERENCES

Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1995
VIEW 1 EXCERPT